Skip to main content

Advertisement

SpringerLink
Log in

Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid

  • Oculoplastics and Orbit
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) function in the remodelling of the extracellular matrix in morphogenesis, angiogenesis, tissue repair, and tumor invasion. Elevated levels of distinct MMPs in tumor tissue are related to worse prognosis. However, no overall consistent pattern of expression in human cancer has been identified. The aim of the present study was to evaluate the expression of MMP-1, -9, -13 and TIMP-1 in tumor epithelial cells and surrounding connective tissue in primary basal cell carcinomas (BCC) of the eyelid, and to assess their role as prognostic markers for tumor recurrence.

Methods

Surgical specimens of 49 histologically proven primary BBCs of the eyelid of different histological subtypes were included. Immunohistological studies were performed using antibodies against MMP-1, MMP-9, MMP-13 and TIMP-1, and staining intensity was analyzed semi-quantitatively.

Results

MMP-1, -9, -13, and TIMP-1 were expressed at various intensities in epithelial tumor cells and surrounding stromal cells including fibroblasts, inflammatory cells, and vascular endothelial cells in all tumor subtypes. Staining was especially prominent at the invading edge of the BCC. A statistically significant correlation was seen between increased TIMP-1 expression in tumor and/or stromal cells with the presence of MMP-13 (p = 0.007 and p < 0.0001 respectively). Moreover, TIMP-1 expression in tumor and/or stroma was significantly associated with relapse (p = 0.012 and p = 0.042 respectively).

Conclusion

MMP-9, MMP-13 and TIMP-1 expression may serve as a prognostic marker for early tumor invasiveness. Moreover, up-regulation of TIMP-1 in tumor and/or surrounding stromal cells may indicate an increased risk for BCC recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Farhi D, Dupin N, Palangie A, Carlotti A, Avril MF (2007) Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg 33:1207–1214

    Article  PubMed  CAS  Google Scholar 

  2. Nagore E, Grau C, Molinero J, Fortea JM (2003) Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk. A retrospective study of 248 patients. J Eur Acad Dermatol Venereol 17:167–170

    Article  PubMed  CAS  Google Scholar 

  3. Sexton M, Jones DB, Maloney ME (1990) Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 23:1118–1126

    Article  PubMed  CAS  Google Scholar 

  4. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  PubMed  CAS  Google Scholar 

  5. Werb Z (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91:439–442

    Article  PubMed  CAS  Google Scholar 

  6. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149

    PubMed  CAS  Google Scholar 

  7. Stetler-Stevenson WG, Yu AE (2001) Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 11:143–152

    Article  PubMed  CAS  Google Scholar 

  8. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699–704

    Article  PubMed  CAS  Google Scholar 

  9. Nabeshima K, Lane WS, Biswas C (1991) Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor. Arch Biochem Biophys 285:90–96

    Article  PubMed  CAS  Google Scholar 

  10. Brennan M, Bhatti H, Nerusu KC, Bhagavathula N, Kang S, Fisher GJ, Varani J, Voorhees JJ (2003) Matrix metalloproteinase-1 is the major collagenolytic enzyme responsible for collagen damage in UV-irradiated human skin. Photochem Photobiol 78:43–48

    Article  PubMed  CAS  Google Scholar 

  11. Culhaci N, Metin K, Copcu E, Dikicioglu E (2004) Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC Cancer 4:42

    Article  PubMed  Google Scholar 

  12. Dumas V, Kanitakis J, Charvat S, Euvrard S, Faure M, Claudy A (1999) Expression of basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous basal and squamous cell carcinomas. Anticancer Res 19:2929–2938

    PubMed  CAS  Google Scholar 

  13. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kahari VM (1997) Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 151:499–508

    PubMed  CAS  Google Scholar 

  14. Kobayashi T, Onoda N, Takagi T, Hori H, Hattori S, Nagai Y, Tajima S, Nishikawa T (1996) Immunolocalizations of human gelatinase (type IV collagenase, MMP-9) and TIMP (tissue inhibitor of metalloproteinases) in normal epidermis and some epidermal tumors. Arch Dermatol Res 288:239–244

    Article  PubMed  CAS  Google Scholar 

  15. Monhian N, Jewett BS, Baker SR, Varani J (2005) Matrix metalloproteinase expression in normal skin associated with basal cell carcinoma and in distal skin from the same patients. Arch Facial Plast Surg 7:238–243

    Article  PubMed  Google Scholar 

  16. Yucel T, Mutnal A, Fay K, Fligiel SE, Wang T, Johnson T, Baker SR, Varani J (2005) Matrix metalloproteinase expression in basal cell carcinoma: relationship between enzyme profile and collagen fragmentation pattern. Exp Mol Pathol 79:151–160

    Article  PubMed  CAS  Google Scholar 

  17. Hattori Y, Nerusu KC, Bhagavathula N, Brennan M, Hattori N, Murphy HS, Su LD, Wang TS, Johnson TM, Varani J (2003) Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma. Exp Mol Pathol 74:230–237

    Article  PubMed  CAS  Google Scholar 

  18. Telfer NR, Colver GB, Morton CA (2008) Guidelines for the management of basal cell carcinoma. Br J Dermatol 159:35–48

    Article  PubMed  CAS  Google Scholar 

  19. Moon SE, Dame MK, Remick DR, Elder JT, Varani J (2001) Induction of matrix metalloproteinase-1 (MMP-1) during epidermal invasion of the stroma in human skin organ culture: keratinocyte stimulation of fibroblast MMP-1 production. Br J Cancer 85:1600–1605

    Article  PubMed  CAS  Google Scholar 

  20. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ (1998) Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95:365–377

    Article  PubMed  CAS  Google Scholar 

  21. Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103:1237–1241

    Article  PubMed  CAS  Google Scholar 

  22. Taraboletti G, Sonzogni L, Vergani V, Hosseini G, Ceruti R, Ghilardi C, Bastone A, Toschi E, Borsotti P, Scanziani E, Giavazzi R, Pepper MS, Stetler-Stevenson WG, Bani MR (2000) Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells. Exp Cell Res 258:384–394

    Article  PubMed  CAS  Google Scholar 

  23. Bertaux B, Hornebeck W, Eisen AZ, Dubertret L (1991) Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97:679–685

    Article  PubMed  CAS  Google Scholar 

  24. Kleiner DE Jr, Stetler-Stevenson WG (1993) Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 5:891–897

    Article  PubMed  CAS  Google Scholar 

  25. Mauch C, Krieg T, Bauer EA (1994) Role of the extracellular matrix in the degradation of connective tissue. Arch Dermatol Res 287:107–114

    Article  PubMed  CAS  Google Scholar 

  26. Griffiths RW, Suvarna SK, Stone J (2005) Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg 58:795–805

    Article  PubMed  CAS  Google Scholar 

  27. Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS (1992) Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol 18:471–476

    PubMed  CAS  Google Scholar 

  28. Walker P, Hill D (2006) Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol 47:1–12

    Article  PubMed  Google Scholar 

  29. Auw-Haedrich C, Frick S, Boehringer D, Mittelviefhaus H (2009) Histologic safety margin in basal cell carcinoma of the eyelid: correlation with recurrence rate. Ophthalmology 116:802–806

    Article  PubMed  Google Scholar 

  30. Swetter SM, Boldrick JC, Pierre P, Wong P, Egbert BM (2003) Effects of biopsy-induced wound healing on residual basal cell and squamous cell carcinomas: rate of tumor regression in excisional specimens. J Cutan Pathol 30:139–146

    Article  PubMed  Google Scholar 

  31. Fernandes JD, de Lorenzo Messina MC, de Almeida Pimentel ER, Castro LG (2008) Presence of residual basal cell carcinoma in re-excised specimens is more probable when deep and lateral margins were positive. J Eur Acad Dermatol Venereol 22:704–706

    Article  PubMed  CAS  Google Scholar 

  32. Deng JS, Falo LD Jr, Kim B, Abell E (1998) Cytotoxic T cells in basal cell carcinomas of skin. Am J Dermatopathol 20:143–146

    Article  PubMed  CAS  Google Scholar 

  33. Macpherson N, Lamrock E, Watt G (2010) Effect of inflammation on positive margins of basal cell carcinomas. Australas J Dermatol 51:95–98

    Article  PubMed  Google Scholar 

  34. Paavilainen V, Aaltonen M, Tuominen J, Saari KM (2007) Histological characteristics of basal cell carcinoma of the eyelid. Ophthalmic Res 39:45–48

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Otorhinolaryngology and Ophthalmology, Medical University, Varna, Bulgaria

    Zornitsa I. Zlatarova

  2. Department of General and Clinical Pathology, Medical University, Varna, Bulgaria

    Ekaterina B. Softova

  3. Department of Social Medicine and Health Care Organization, Medical University, Varna, Bulgaria

    Klara G. Dokova

  4. Department of Ophthalmology, Ludwig-Maximilians-University, Klinikum der Universität München, Campus Innenstadt, Mathildenstrasse 8, 80336, Munich, Germany

    Elisabeth M. Messmer

Authors
  1. Zornitsa I. Zlatarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ekaterina B. Softova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Klara G. Dokova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth M. Messmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabeth M. Messmer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zlatarova, Z.I., Softova, E.B., Dokova, K.G. et al. Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid. Graefes Arch Clin Exp Ophthalmol 250, 425–431 (2012). https://doi.org/10.1007/s00417-011-1810-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-011-1810-x

Keywords

Search

Navigation